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Abstract
Glycogenbranchingenzyme1 (GBE1) plays anessential role in glycogenbiosynthesis by generatingα-1,6-glucosidic branches from
α-1,4-linked glucose chains, to increase solubility of the glycogen polymer. Mutations in the GBE1 gene lead to the heterogeneous
early-onset glycogen storage disorder type IV (GSDIV) or the late-onset adult polyglucosan body disease (APBD). To better understand
this essential enzyme, we crystallized human GBE1 in the apo form, and in complex with a tetra- or hepta-saccharide. The GBE1
structure reveals a conserved amylase core that houses the active centre for the branching reaction andharbours almost all GSDIV
andAPBDmutations.Anon-catalytic binding cleft, proximal to the site of the commonAPBDmutationp.Y329S,was found to bind
the tetra- and hepta-saccharides andmay represent a higher-afﬁnity site employed to anchor the complex glycogen substrate for
the branching reaction. Expression of recombinant GBE1-p.Y329S resulted in drastically reduced protein yield and solubility
compared with wild type, suggesting this disease allele causes protein misfolding and may be amenable to small molecule
stabilization. To explore this, we generated a structural model of GBE1-p.Y329S and designed peptides ab initio to stabilize the
mutation. As proof-of-principle, we evaluated treatment of one tetra-peptide, Leu-Thr-Lys-Glu, in APBD patient cells. We
demonstrate intracellular transport of this peptide, its binding and stabilization of GBE1-p.Y329S, and 2-fold increased mutant
enzymatic activity compared with untreated patient cells. Together, our data provide the rationale and starting point for the
screening of small molecule chaperones, which could become novel therapies for this disease.
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Introduction
Glycogen is a compact polymer of α-1,4-linked glucose units
regularly branched with α-1,6-glucosidic bonds, serving as the
main carbohydrate store and energy reserve across many
phyla (1). In eukaryotes, glycogenin (EC 2.4.1.186) initiates the syn-
thesis of the linear glucan chain (2), which is elongated by glyco-
gen synthase (GYS, EC 2.4.1.11) (3), functioning in concert with
glycogen branching enzyme (GBE, EC 2.4.1.18) to introduce side
chains (4). GBE (also known as 1,4-glucan:1,4-glucan 6-glucano-
transferase) transfers α-1,4-linked glucose units from the outer
‘non-reducing’ end of a growing glycogen chain into an α-1,6 pos-
ition of the same or neighbouring chain, thereby creating glyco-
gen branches. Together GYS and GBE deﬁne the globular and
branched structure of glycogen, which increases its solubility by
creating a hydrophilic surface (5) and regulates its synthesis by
increasing the number of reactive termini for GYS-mediated
chain elongation (6). Similar branching enzyme activities are
also found in plants, using amylopectin as substrate (7).
Inheritedmutations in the humanGBE1 (hGBE1) gene (chromo-
some 3p12.3) (5) cause the autosomal recessive glycogen storage
disorder type IV (GSDIV; OMIM 232500) (8,9). GSDIV constitutes
∼3% of all GSD cases (10) and is characterized by the deposition
of an amylopectin-like polysaccharide that has fewer branch
points, longer outer chains and poorer solubility than normal
glycogen. This malconstructed glycogen (termed polyglucosan),
presumably the result of GYS activity outpacing that of mutant
GBE, accumulates in most organs including liver, muscle, heart
and the central and peripheral nervous systems, leading to tissue
and organ damage, and cell death. GSDIV is an extremely hetero-
geneous disorderwith variable onset age and clinical severity, in-
cluding a classical hepatic form in neonates and children that
progresses to cirrhosis (Andersen disease) (11), a neuromuscular
form classiﬁed into four subtypes (perinatal, congenital, juvenile,
adult onset) (12), aswell as a late-onset allele variant—adult poly-
glucosan body disease (APBD, OMIM 263570)—a neurological dis-
order affecting mainly the Ashkenazi Jewish population (13). To
date there is no transformative treatment for GSDIV and APBD.
A majority of disease-causing mutations are of the missense
type, likely to affect the GBE protein structure and function (14).
GBE is classiﬁed as a carbohydrate-active enzyme (http://www.
cazy.org) and catalyses two reactions presumably within a single
active site. In the ﬁrst reaction (amylase-type hydrolysis), GBE
cleaves every 8–14 glucose residues of a glucan chain, an α-1,4-
linked segment of more than six glucose units from the non-
reducing end. In the second reaction (transglucosylation), it trans-
fers the cleaved oligosaccharide (‘donor’), via an α-1,6-glucosidic
linkage, to the C6 hydroxyl group of a glucose unit (‘acceptor’)
within the same chain (intra-) or onto a different neighbouring
chain (inter-). The mechanistic determinants of the branching
reaction, e.g. length of donor chain, length of transferred chain,
distance between two branch points, relative occurrence of
intra- versus inter-chain transfer and variation among organisms,
remain poorly understood.
Almost all sequence-annotated branching enzymes, includ-
ing those from diverse organisms, belong to the GH13 family of
glycosyl hydrolases (also known as the α-amylase family) (5)
and fall either into subfamily 8 (eukaryotic GBEs) or subfamily 9
(prokaryotic GBEs) (15). The GH13 family is the largest glysoyl
hydrolase family, comprised of amylolytic enzymes (e.g. amylase,
pullulanase, cyclo-maltodextrinase and cyclodextrin glycosyl-
transferase) that carry out a broad range of reactions on α-glyco-
sidic bonds, including hydrolysis, transglycosylation, cyclization
and coupling. These enzymes share a (β/α)8 barrel domain with
an absolutely conserved catalytic triad (Asp-Glu-Asp) at the
C-terminal face of the barrel (16). In several GH13 enzymes, this
constellation of three acidic residues functions as the nucleophile
(Asp357, hGBE1numberinghereinafter), proton donor (Glu412) and
transition state stabilizer (Asp481) in the active site. To date, crystal
structures available from GH13-type GBEs from plant (17) and
bacteria (18,19) have revealed an overall conserved architecture;
however, no mammalian enzyme has yet been crystallized. In
this study, we determined the crystal structure of hGBE1 in
complex with oligosaccharides, investigated the structural and
molecular bases of disease-linked missense mutations and pro-
vided proof-of-principle rescue of mutant hGBE1 activity by
rational peptide design.
Results and Discussion
hGBE1 structure determination
For structural studies, we pursued baculovirus-infected insect
cell overexpression of hGBE1, a 702-amino acid (aa) protein. Inter-
rogation of several N- and C-terminal boundaries (Supplementary
Material, Fig. S1) in this expression system yielded a soluble and
crystallisable polypeptide for hGBE1 from aa 38–700 (hGBE1trunc).
Using the molecular replacement method with the Oryza sativa
starch branching enzyme I (SBE1; PDB: 3AMK; 54% identity to
hGBE1) as search model, we have determined the structure of
hGBE1trunc in the apo form (hGBE1-apo), and in complex with the
tetra-saccharide acarbose (hGBE1-ACR) or hepta-saccharide mal-
toheptaose (hGBE1-Glc7), to the resolution range of 2.7–2.8 Å (Sup-
plementary Material, Table S1). Inspection of the asymmetric unit
content as well as symmetry-related protomers did not reveal any
stable oligomer arrangements, consistent with GBE1 being a
monomer in size-exclusion chromatography (data not shown),
similar to most GH13 enzymes.
hGBE1 is an elongated molecule (longest dimension >85 Å)
composed of four structural regions (Fig. 1A and B): theN-termin-
al helical segment (aa 43–75), a carbohydrate-binding module 48
(CBM48; aa 76–183), a central catalytic core (aa 184–600) and the
C-terminal amylase-like barrel domain (aa 601–702). A structural
overlay of hGBE1 with reported branching enzyme structures
from O. sativa SBE1 (17) (PDB: 3AMK, Cα-RMSD: 1.4 Å, sequence
identity: 54%) and M. tuberculosis GBE (19) (3K1D, 2.1 Å, 28%)
(Fig. 1C) highlights the conserved catalytic core housing the ac-
tive site within a canonical (βα)6 barrel (16). Nevertheless, the dif-
ferent branching enzymes show greater structural variability in
the N-terminal region preceding the catalytic core, as well as in
two surface-exposed loops of the TIM barrel (Fig. 1C). For ex-
ample, in O. sativa SBE1 and human GBE1 structures, the helical
segment precedes the CBM48 module, whereas in M. tuberculosis
GBE, the helical segment is replaced by an additional β-sandwich
module (N1 in Fig. 1C and D). The closer homology of hGBE1 with
O. sativa SBE1, whose substrate is starch, than with the bacterial
paralog M. tuberculosis GBE, suggests a similar evolutionary con-
servation in the branching enzyme mechanism for glycogen
and starch, both involving a growing linear α1,4-linked glucan
chain as substrate.
Oligosaccharide binding of hGBE1 at catalytic and
non-catalytic sites
To characterize the binding of oligosaccharides to branching en-
zymes, we co-crystallized hGBE1trunc with acarbose (ACR) or mal-
toheptaose (Glc7) (Fig. 2A). ACR is a pseudo-tetra-saccharide
acting as active site inhibitor for certain GH13 amylases. In the
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hGBE1-ACR structure, acarbose is bound not at the expected ac-
tive site but instead at the interface between the CBM48 and
the catalytic domains (Fig. 2B). Within this oligosaccharide bind-
ing cleft (Fig. 2C), ACR interacts with protein residues from the
N-terminal helical segment (Asn62 and Glu63), CBM48 domain
(Trp91, Pro93, Tyr119, Gly120 and Lys121) as well as catalytic
core (Trp332, Glu333 and Arg336). These interactions, likely to
be conserved among species (Fig. 2D), include hydrogen bonds
to the sugar hydroxyl groups as well as hydrophobic/aromatic
interactions with the pyranose rings. The hGBE1-Glc7 structure
reveals similar conformation and binding interactions of malto-
heptaose for its ﬁrst four 1,4-linked glucose units (Fig. 2B). The
three following glucose units, however, extend away from the
protomer surface and engage in interactionswith a neighbouring
non-crystallographic symmetry (NCS)-related protomer in the
asymmetric unit (Supplementary Material, Fig. S2A). These arti-
factual interactionsmediated by crystal packing are unlikely to be
physiologically relevant.
CBM48 is a β-sandwich module found in several GH13 amylo-
lytic enzymes (20). The acarbose binding cleft observed here is
the same location that binds maltopentaose in the O. sativa
SBE1 structure (21), as well as other oligosaccharides in CBM48-
containing proteins (Supplementary Material, Fig. S2B). The
conserved nature of this non-catalytic cleft among branching en-
zymes (Fig. 2D), and its presumedhigher afﬁnity for oligosacchar-
ides than the active site, may represent one of the multiple non-
catalytic binding sites on the enzyme surface. They may provide
GBEs the capability to anchor a complex glycogen granule and, as
proposed previously (22), determine the chain length speciﬁcity
for the branching reaction as a ‘molecular ruler’. This agrees
with the emerging concept of glycogen serving not only as the
substrate and product of its metabolism but also as a scaffold
for all acting enzymes.
In light of our unsuccessful attempts to co-crystallize hGBE1
with an active site-bound oligosaccharide, our analysis of the ac-
tive site is guided by reported structures of GH13 α-amylases in
complex with various oligosaccharides (23,24) (Supplementary
Material, Fig. S3A). The catalytic domain TIM barrel of hGBE1
superimposes well with those from the amylase structures
(RMSD 1.2 Å for 130–150 Cα atoms; Supplementary Material,
Fig. S3B), suggesting a similar mode of substrate threading
along the GH13 enzyme active sites, at least within the proximity
of glycosidic bond cleavage. The hGBE1 active site is a prominent
surface groove at the (βα)6-barrel that could bind a linear glucan
chain via a number of subsites (Fig. 2E, left), each binding a single
glucose unit. The subsites are named ‘–n’, . . . ‘−1’, ‘+1’, . . . ‘+n’,
denoting the n-th glucose unit in both directions from the scissile
glycosidic bond. The most conserved among GH13 enzymes
is the ‘−1’ subsite, which harbours seven strictly conserved
residues forming the catalyticmachinery (16) (Fig. 2F and Supple-
mentary Material, Fig. S4A). The other subsites lack a signiﬁcant
degree of sequence conservation, suggesting that substrate rec-
ognition other than at the ‘−1’ subsite ismediated by surface top-
ology and shape complementarity, and not sequence-speciﬁc
interactions.
The hGBE1 active site is tasked to catalyse two reaction steps
(hydrolysis and transglucosylation) on a growing glucan chain
(Supplementary Material, Fig. S5). The ﬁrst reaction is a nucleo-
philic attack on the ‘−1’ glucose at the C-1 position by an
aspartate (Asp357), generating a covalent enzyme–glycosyl inter-
mediate with release of the remainder of the glucan chain carry-
ing the reducing end (+1, +2 . . .). In the second reaction, the
Figure 1.Crystal structure of hGBE1. (A andB) Orthogonal views of hGBE1 showing theN-terminal helical segment (orange), CBM48 (pink), central catalytic domain (green)
andC-terminal domain (blue). The catalytic triadAsp357-Glu412-Asp481 is shownas red sticks. Numbers refer to domain boundaries. N- andC-termini are labelled as grey
spheres. (C) Superposition of branching enzyme structures from human (hGBE1, this study), O. sativa SBE1 and M. tuberculosis GBE, highlighting the conserved domain
architecture and three regions of structural variation. (D) Domain organization of hGBE1, O. sativa SBE1 and M. tuberculosis GBE revealing differences in the N-terminus
betweenprokaryotic and eukaryotic polypeptides. Prokaryotic GBEs contain twoN-terminal carbohydrate-binding domains (N1, N2)whereas eukaryotes contain only one
(CBM48) and replace the prokaryotic N1 domain with a helical extension.
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enzyme-linked ‘−1’ glucose is attacked by a glucose 6-hydroxyl
group from either the same or another glucan chain, which acts
as a nucleophile for the chain transfer. While both hGBE1 reac-
tions presumably proceed via a double displacementmechanism
involving the strictly conserved triad Asp357-Glu412-Asp481, as
proposed for GH13 amylases, there exist mechanistic differences
between branching and amylolytic enzymes: (i) the branching
enzyme substrate is not a malto-oligosaccharide, but rather a
complex glycogen granule with many glucan chains and (ii) the
transglycosylation step in GBE (glucose 6-OH as acceptor) is re-
placed by hydrolysis in amylases (H2O as acceptor). These differ-
ences require that the active site entrance of hGBE1 be tailor-
made to accommodate the largermore complex glucose acceptor
chain (Fig. 2E), as opposed to a water molecule in amylases. A re-
gion of GBE-unique sequences (aa 405–443), rich in Gly/Ala resi-
dues, has been identiﬁed based on alignment with GH13
sequences (25) (Supplementary Material, Fig. S4B). This region,
replaced in amylolytic enzymes by sequence insertions and bulk-
ier residues, maps onto a hGBE1 surface that is proximal to the
‘+1, +2 . . .’ subsites, and to the β4-α4 loop that is disordered in
hGBE1 but adopts different conformations in the O. sativa and
M. tuberculosis structures (Figs. 1B and 2E, right). We posit that
this surface region, unique to branching enzymes, facilitates ac-
cess to the active site by an incoming glucan acceptor chain.
While beyond the scope of this work, it will be of interest to
determine how this GBE-unique region and the non-catalytic
oligosaccharide binding cleft function together to bind the com-
plex glycogen granule.
GBE1 missense mutations are predominantly localized
in the catalytic core
The hGBE1 crystal structure provides a molecular framework to
understand the pathogenic mutations causing GSDIV and
APBD, as the previously determined bacterial GBE structures
have low amino acid conservation in some of the mutated posi-
tions. Apart from a few large-scale aberrations (nonsense, frame-
shift, indels, intronic mutations), which likely result in truncated
and non-functional enzyme, there are to date 25 reported GBE1
missense mutations, effecting single amino acid changes at 22
different residues (SupplementaryMaterial, Table S2). Thesemu-
tation sites are predominantly localized in the catalytic core
(Fig. 3A), with a high proportion around exon 12 (n = 6 in exon
12, n = 2 in exon 13, n = 1 in exon 14) (26). There is no apparent cor-
relation among the genotype, amino acid change and its asso-
ciated disease phenotype. However, inspection of the atomic
environment surrounding these residues, some of which are
strictly invariant among GBE orthologs (Supplementary Material,
Fig. S6), allows us to postulate their molecular effects. They can
be classiﬁed into ‘destabilising’ substitutions, which likely
Figure 2.Oligosaccharide binding to hGBE1. (A) Chemical structures of acarbose (ACR) and (Glc7). (B) Surface representation of hGBE1 (Fig. 1A colouring) showing the bound
oligosaccharides. (C) ACR binding cleft at the interface of the helical segment (orange), CBM48 (pink) and catalytic domain (green). Shown in sticks are ACR (yellow carbon
atoms) and its contact protein residues (white carbon atoms). Inset, 2Fo-Fc electron density for the modelled ACR. (D) Sequence alignment of the ACR-binding residues
of hGBE1 (underlined). Annotated branching enzyme sequences are from human (Uniprot ID Q04446), O. sativa SBE1 (Q01401), D. melanogaster (A1Z992), D. rerio (F8W5I0),
M. tuberculosis (P9WN45) and E. coli (P07762). (E) Surface representation of the hGBE1–Glc7 complex to model the two GBE reaction steps. Left panel is overlayed with a
decasaccharide ligand (blue and orange stick) and TIM barrel loops (green ribbon) from the B. amyloliquefaciens and B. licheniformis chimeric amylase structure (PDB
code 1e3z) to highlight the broader active site cleft in hGBE1 owing to the absence of these amylase loops. Right panel is overlayed with maltotriose (cyan stick) from
pig pancreatic α-amylase (PDB code 1ua3), as well as the β4-α4 loop from O. sativa SBE1 (purple) and M. tuberculosis GBE (yellow) structures, which is disordered in
hGBE1. Superposition of hGBE1 with structural homologs is illustrated in Supplementary Material, Figure S3. (F) Close-up view of the hGBE1 active site barrel (cyan
strands) that harbours the conserved residues (sticks) of the ‘−1’ subsite. Residues constituting the putative catalytic triad are coloured magenta.
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disrupt protein structure, and ‘catalytic’ substitutions, which are
located proximal to the active site andmayaffect oligosaccharide
binding or catalysis. The most common type of ‘destabilising’
mutations is those disrupting H-bond networks (p.Q236H,
p.E242Q, p.H243R, p.H319R/Y, p.D413H, p.H545R, p.N556Y,
p.H628R; Fig. 3B) and ionic interactions (p.R262C, p.R515C/H,
p.R524Q, p.R565Q) within the protein core, whereas disruption
of aromatic or hydrophobic interactions are also common
(p.F257L, p.Y329S/C, p.Y535C, p.P552L; Fig. 3C). Also within the
protein core, mutation of a large buried residue to a small one
creates a thermodynamically unfavoured cavity (p.M495T,
p.Y329S/C; Fig. 3D), whereas mutation from a small residue to a-
bulkier one creates steric clashes with the surroundings
(p.G353A, A491Y, p.G534V; Fig. 3E). In certain cases, mutation to
a proline within an α-helix likely disrupts local secondary struc-
ture (e.g. p.L224P), whereas mutation from glycine can lose im-
portant backbone ﬂexibility (e.g. p.G427R, likely causing Gln426
from the catalytic domain to clash with Phe45 in the helical seg-
ment). The ‘catalytic’mutations aremore difﬁcult to deﬁne in the
absence of a sugar bound hGBE1 structure at the active site. How-
ever, superimposing hGBE1 with amylase structures reveals
Arg262, His319, Asp413 and Pro552 as mutation positions that
could line the oligosaccharide access to the active site (Fig. 3A,
inset). In particular, the imidazole side-chain of His319 is oriented
towards the active site andwithin 8 Å distance from the −1 site. Its
substitution to a charged (p.H319R) or bulky (p.H319Y) amino acid
could potentially destabilize oligosaccharide binding.
GBE1 p.Y329S is a destabilizing mutation
The c.986A>Cmutation results in the p.Y329S amino acid substi-
tution, the most common APBD-associated mutation (27). This
residue is highly conserved across different GBE orthologs
supporting its associated pathogenicity (Fig. 4A). We observed
drastically reduced recombinant expression and protein solubil-
ity fromanhGBE1 construct harbouring the p.Y329S substitution,
comparedwith wild type (Fig. 4B).We therefore sought amolecu-
lar explanation by inspecting our hGBE1 structure. Tyr329 is a
surface-exposed residue in the catalytic domain and confers
stability to the local environment by interacting with the hydro-
phobic residues Phe327, Val334, Leu338, Met362 and Ala389.
Additionally, the tyrosyl hydroxyl group hydrogen bonds
with the His289 backbone oxygen (Fig. 4C, left). Mutation of
Tyr329 to the smaller amino acid serine (Ser329mutant) likely
removes these interactions (Fig. 4C, right) and creates a solvent
accessible cavity within this hydrophobic core (Fig. 4D), both
of which could lead to destabilized protein. Together, our
expression and structural analyses demonstrate that the p.Y329S
mutation commonly associated with APBD results in protein
destabilization.
Figure 3. Structural analysis of hGBE1 mutations. (A) Mapping of disease-associated missense mutation sites (red sticks) on the hGBE1 structure underlines their
prevalence in the central catalytic core. Inset—view of the hGBE1 sites showing four missense mutation sites (red sticks), which could be involved in binding a glucan
chain, indicated by an overlayed decasacharide ligand from the 1e3z structure. (B–D) Structural environment of representative mutation sites, shown in (A) by orange-
dotted circles, to illustrate how a single amino acid substitution (pink sticks) may: abolish hydrogen-bonding interactions (B, p.E242Q), create a water-ﬁlled cavity
within a hydrophobic core (C, p.F257A), abolish hydrophobic interactions (D, p.M495T) and create steric clash with neighbouring residues (E, p.G534V). The mutant
models are generated by simple side-chain replacement from the wild-type coordinates.
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Computational design of hGBE1 p.Y329S-stabilizing
peptide
Wenext investigatedwhether the p.Y329S-associated protein de-
stabilization could be ‘rescued’ by pharmacological chaperone
treatment (28). To facilitate the design of a small molecule/pep-
tide chaperone, which could confer stability to the Ser329mutant
site, we ﬁrst generated a structural model of hGBE1-Y329S from
the wild-type hGBE1-apo coordinates. Using the assumption
that the hGBE1-apo crystal structure represents an active enzyme
conformation, the design of an hGBE1 p.Y329S-stabilizing
peptide was performed using a rigid backbone modelling of the
mutation, in order to retain maximum similarity to the active
enzyme.
Screening around the solvent exposed Ser329mutant region in
our hGBE1-Y329S structuralmodel, the ab initio peptide design al-
gorithm gave as best hit a Leu-Thr-Lys-Glu (LTKE) peptide among
the six top scores (Supplementary Material, Table S3), in terms of
favourable binding afﬁnities and solubility. Molecular dynamics
simulation of wild-type hGBE1, hGBE1-Y329S and LTKE peptide-
bound hGBE1-Y329S models (Fig. 5A; Supplementary Material,
Methods) corroborated our prediction that LTKE stabilizes
the mutated enzyme. Modelling of the LTKE peptide onto our
hGBE1-Y329S model suggests that the N-terminal Leu (position i)
is the primary contributor to peptide-binding energy (Fig. 5B),
with a calculated dissociation constant (Kd) of 1.6 µ (Supple-
mentary Material, Table S3). Replacement of Leu at position i
with Ala (ATKE peptide) or with acetyl-Leu (Ac-LTKE peptide)
was predicted to severely reduce peptide-binding energy (Sup-
plementary Material, Fig. S7; Supplementary Material, Methods),
strongly suggesting a speciﬁc mode of action for the LTKE pep-
tide. In our LTKE-bound hGBE1-Y329S model, the Leu side-
chain can penetrate the cavity formed by the p.Y329S mutation
(Fig. 5C and D), recovering some of the hydrophobic interactions
(e.g. with Phe327, Met362) offered by the wild-type tyrosyl aro-
matic ring, albeit with a different hydrogen bond pattern
(Fig. 5E). The charged peptidyl N-terminus also hydrogen-bonds
with Ser329mutant and forms a salt bridge with Asp386. The pep-
tidyl Thr at position ii hydrogen bonds to Asp386, whereas the
side chains of Lys at position iii and Glu at position iv further pro-
vide long-range electrostatic interactions with hGBE1.
Peptide rescue of hGBE1 p.Y329S
We evaluated the potential of the LTKE peptide to rescue the de-
stabilized mutant protein in vivo, by testing it in APBD patient
cells harbouring the p.Y329S mutation. To conﬁrm that the pep-
tide is internalized into cells, we determined its sensitivity to
uptake temperature in peripheral blood mononuclear cells
(PBMCs) and observed a time-dependent increase in the uptake
of the C-terminal ﬂuorescein isothiocyanate (FITC)-labelled pep-
tide (LTKE-FITC) at 37°C but not 4°C, suggesting it is actively
transported into cells (Fig. 6A). These peptide levels were sufﬁ-
cient to partially rescue mutant p.Y329S protein level in vivo as
determined by Western blot analysis (Fig. 6B). Pre-incubation of
PBMCs with the LTKE peptide resulted in detectable mutant
GBE1 protein, which was absent when the ‘reverse peptide’
(EKTL) was used, or in patient-derived cells with no peptide treat-
ment. More importantly, the LTKE and LTKE-FITC peptides
Figure 4. p.Y329S mutation results in destabilized hGBE1 protein. (A) Tyr329 is highly conserved across various GBE orthologs (Uniprot ID for each sequence is shown).
(B) SDS–PAGE of afﬁnity-puriﬁed hGBE1WT and p.Y329S, showingmuch reduced level of soluble mutant protein. (C) Structural analysis of Tyr329 and its neighbourhood
reveals a number of hydrophobic interactions that are removed by its substitution with serine. (D) Tyr329 (magenta, left panel) is accessible to the protein exterior, and its
mutation to Ser329 (magenta, right panel) creates a cavity (circled).
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enhanced GBE1 activity by 2-fold, compared with untreated or
EKTL-treated mutant cells (>15% of unaffected control) (Fig. 6C).
As these ameliorating effects of LTKE were sequence speciﬁc,
we conjecture that they arose from the predicted hGBE1-Y329S
binding model described in Figure 5, although attempts to
prove this directly in vitrowere hampered by difﬁculty in obtain-
ing puriﬁed recombinant mutant protein (Fig. 4D). We resolved
this by applying the hapten immunoassay (30) (Fig. 6D and E),
to show that the LTKE-FITC peptide, but not the FITC-labelled
control peptides ATKE, Ac-LTKE and EKTLwith predicted inferior
binding to hGBE1-Y329Smodel (SupplementaryMaterial, Fig. S7),
were able to out-compete LTKE binding in patient skin
ﬁbroblasts. This competitive binding of LTKE, speciﬁc to mutant
cells and to the peptide amino acid sequence, clearly indicates
the binding speciﬁcity of the LTKE peptide towards hGBE1
p.Y329S. The apparent Kd of peptide binding determined by the
hapten immunoassay was 18 µ (Fig. 6E), within the range of
error from the calculated Kd (1.6 µ; Supplementary Material,
Table S3). Collectively, our data suggest that the LTKE peptide
can potentially function as a stabilizing chaperone for the
mutant p.Y329S protein.
Concluding remarks
In this work, we combined structural, biochemical and cellular
approaches to demonstrate for the ﬁrst time that a GBE1 muta-
tion can result in protein destabilization, lending support to the
emerging concept, among many metabolic enzymes, that muta-
tion-induced protein destabilization could playa causative role in
disease pathogenesis (31). In this hypothesis, mutant destabi-
lized proteinsmaymisfold or aggregate and thus are subsequent-
ly degraded by the quality control machinery in the cell.
Pharmacologic approaches to stabilize the partial misfolding
using small molecule chaperones attempt to divert the mutant
polypeptide from degradation pathways and deliver it to its na-
tive subcellular destination, ideally allowing a sufﬁcient recovery
of physiological function to prevent the disease state (28). Here,
we provide proof of principle for use of a small peptide as chap-
erone therapy in APBD, showing that the LTKE peptide can rescue
GBE1mutant activity to 10–15% of wild type.We propose that the
LTKE peptide binds to mutant GBE1 possibly in a co-translational
manner, akin to the binding of cellular chaperones to nascent
polypeptide chains during protein synthesis (32), thereby
allowing peptide access to the mutation-induced cavity as the
protein is being folded in the cell. In some metabolic disorders
[e.g. lysosomal storage diseases, (33)], a 10–15% recovery of mu-
tant enzyme activity was sufﬁcient to ameliorate disease pheno-
types. Speciﬁcally, in APBD, where patients homozygous for the
p.Y329S mutation reportedly have GBE activity up to even 18%
(34), a further 2-fold increase in activity with the peptide may
be clinically signiﬁcant, especially in conjunction with other
therapies, as heterozygous carriers with only 50% GBE activity
are non-symptomatic (27). Additionally, a peptide-mediated
10–15% improvement of GBE activity from null (e.g. p.F257L in
GSDIV) might change a fatal childhood disease such as GSDIV,
to a relatively more tolerable adult onset disease such as APBD.
In general, we believe small peptide-based therapy has a
promising therapeutic potential: It has the beneﬁts of low tox-
icity, low production costs and the possibility of incorporation
into gene therapy, particularly useful in chronic conditions
such as APBD. Nevertheless, peptides also have inherent disad-
vantages, such as poor oral bio-availability and low serum half-
lives, which must be considered in future clinical applications.
In summary, with a recombinant expression system and 3D
structural information now available for human GBE1, a system-
atic, pharmacophore-based high-throughput screening regime
using activity and stabilization as readout could be implemented
in the future, to search for pharmacological chaperones that can
target GBE1 as potential treatment for GSDIV and APBD.
Material and Methods
Recombinant hGBE1 production, crystallization and
characterization
DNA fragment encoding aa 38–700 of human GBE1 (hGBE1trunc)
was ampliﬁed from a cDNA clone (IMAGE: 4574938) and sub-
cloned into the pFB-LIC-Bse vector (Gen Bank accession number
EF199842) in framewith an N-terminal His6-tag and a TEV prote-
ase cleavage site. Full-length hGBE1 was constructed in the
Figure 5. In silico peptide design to ﬁll the Ser239mutant cavity. (A) Root mean-
squared deviation (RMSD) from the backbone as a representation of structural
stability (29). The dynamic conformations of the three structural models (hGBE1
WT, hGBE1-Y329S and peptide-bound hGBE1-Y329S) at 0.5-ns intervals along
the simulation were superimposed with the initial backbone of the WT
structure, in order to obtain RMSD values. (B) The molecular mechanics force
ﬁeld calculated binding free energy contributions of individual amino acids in
the tetra-peptide LTKE. The Leu N-terminus contributes more than half of total
binding free energy. (C) Homology model of hGBE1-Y329S in complex with the
LTKE peptide (purple sticks) at the Ser329mutant cavity. (D) Close-up view of the
LTKE peptide, where the side-chain of the N-terminal leucine (Leui) residue ﬁlls
the cavity. (E) The LTKE peptide can bind hGBE1 via a number of hydrophobic
and polar interactions (predicted hydrogen bonds in dotted lines).
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pFastBac-1 vector, from which the hGBE1-Y329S mutant was
generated by two sequential PCR reactions using Exact DNApoly-
merase (5 PRIME Co, Germany). hGBE1 protein was expressed in
insect cells in Sf9 media (Life technologies) and puriﬁed by afﬁn-
ity (Ni-NTA; Qiagen) and size exclusion (Superdex200; GE Health-
care) chromatography. hGBE1 was crystallized by vapour
diffusion at 4°C. Diffraction data were collected at the Diamond
Light Source. Phases for hGBE1 were calculated by molecular re-
placement. Atomic coordinates and structure factors have been
deposited in the PDBwith accession codes 4BZY, 5CLT and 5CLW.
Peptide design, synthesis and uptake
Using Pepticom’s proprietary software and its ab initio peptide
design algorithm, a Leu-Thr-Lys-Glu (LTKE) peptide was selected
for synthesis (GL Biochem, China). The effect of LTKE peptidewas
tested in vivo in peripheral blood mononuclear cells (PBMCs) col-
lected from a healthy donor and APBD patients [approved by the
Hadassah–Hebrew University Medical Center Institutional Re-
view Board according to The Code of Ethics of the World Medical
Association (Declaration of Helsinki)]. GBE1 activity was assayed
as described (27). Cellular uptake of FITC-labelled peptide was
measured by ﬂow cytometry. Detailed method information is
provided in Supplementary Materials, Methods.
Hapten immunoassay for establishing competitive
binding
Binding of peptides to hGBE1 p.Y329S in intact ﬁbroblastswas as-
sessed by competitive hapten immunoassay (30). Speciﬁc assay
conditions are described in Figure 6’s legend. In brief, a standard
curvewas ﬁrst generated to show that the immunoreactive LTKE-
FITC peptide in solution can compete for HRP-conjugated FITC
antibody (Jackson Laboratories, West Grove, PA, USA) binding
with solid phase FITC. To generate the standard curve, plates
coated overnight with 12.5 ng/ml BSA-FITC were incubated for
1 h at room temperature with an HRP-conjugated anti-FITC anti-
body pretreated for 2 h with different concentrations of LTKE-
FITC. The HRP substrate tetra-methyl benzidine (TMB) was
added for 0.5 h, and absorbance at 650 nm was measured by
theDTX 880MultimodeDetector (BeckmanCoulter, Indianapolis,
IN, USA). Once competitive binding of the HRP-anti-FITC anti-
body was established by the standard curve, either APBD skin
ﬁbroblasts expressing only hGBE1 p.Y329S or control skin ﬁbro-
blasts expressing only wild-type hGBE1 were incubated with
316 nM LTKE peptide [about a log concentration below the
model-predicted 1.6 µ afﬁnity of LTKE towards hGBE1 p.Y329S
(Supplementary Material, Table S3)] and varying concentrations
of the FITC-labelled LTKE and control peptides. The concentra-
tion range was designated to test displacement of the unlabelled
LTKE peptide from hGBE1 p.Y329S, which generates an immu-
noreactive FITC hapten capable of competing with solid-phase
FITC in the assay. This competition decreases the HRP-conju-
gated FITC antibody binding to solid-phase FITC. To perform
this competition assay, plates coated with BSA-FITC as above
were incubated for 1 h with an HRP-conjugated anti-FITC anti-
body pretreated for 2 h with cell lysates of ﬁbroblasts from
APBD patients homozygous for the GBE p.Y329S mutation and
control patients. These ﬁbroblasts were in turn treated for 2 h
with 316 n LTKE and different concentrations of FITC-labelled
LTKE and control peptides. TMB was then added and absorbance
at 650 nm measured.
Figure 6. Peptide rescue of hGBE1 p.Y329S. (A) PBMCs isolated from APBD patients were incubated with FITC-labelled LTKE peptides at 37°C or 4°C. At the indicated times,
intracellular peptide uptakewas determined by ﬂow cytometry. (B) Isolated PBMCs from an APBD patient (Y329S) or a control subject (WT) were incubated overnight with
or without the peptides indicated (20 µ). Lysed cells were subjected to SDS–PAGE and immunoblotting with anti-GBE1 and anti-α-tubulin (loading control) antibodies.
(C) Isolated PBMCs treated as in (A) were assayed for GBE activity based on (27). (D) Standard curve showing displacement of solid phase FITC by soluble LTKE-FITC. Curve
was ﬁt by non-linear regression using the four-parameter logistic equation: % Absorbance (650) = Bottom + (Top-Bottom)/(1+10^((logEC50-log[LTKE-FITC])*Hillslope),
where Bottom = 7.996, Top = 100, EC50 = 8.460, Hillslope = −1.015. R2 = 0.9934. (E) FITC-labelled peptide competition experiment. Curve ﬁtting, using the homologous
one-site competition model, was found for APBD patient cells competed with LTKE-FITC. APBD patient cells competed with control peptides, or wild-type cells
competed with LTKE-FITC did not demonstrate competitive binding of LTKE-FITC. The competition model equation is: % Absorbance (650) = (Bmax*[LTKE])/([LTKE]+
peptide-FITC (nM) + Kd (nM)), where Bmax = 5229 n, [LTKE] = 316 n, Kd = 18 000 nM, Bottom= 13.24 n. R
2 = 0.9458. In all experiments, cells from n = 3 different APBD
patients (or control unaffected subjects) were used. Error bars indicate SEM.
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